A unit of Mylan (NASDAQ:MYL) is rolling out what it surely hopes will be a popular generic version of a name-brand drug. The company said its Mylan Pharmaceuticals has launched Rabeprazole Sodium Delayed-release Tablets, a version of the branded Aciphex manufactured by Japanese drug maker Eisai.
Rabeprazole sodium is used for the short-term treatment of erosive or ulcerative gastroesophageal reflux disease, and for duodenal ulcers, in patients aged 12 and above. The former is described by the Food and Drug Administration as "a common condition in which the backward flow of acid from the stomach causes heartburn and possible injury to the esophagus."
In addition to Mylan Pharmaceuticals, Dr. Reddy's Laboratories, Kremers Urban Pharmaceuticals, Lupin Pharmaceuticals, Teva USA, and Torrent Pharmaceuticals all received final approval by the FDA last week to sell their versions of the medication.
